Drug Type Small molecule drug |
Synonyms XL 228 |
Mechanism Bcr-Abl T315I inhibitors(BCR-ABL T315I mutation inhibitors), IGF-1R antagonists(Insulin-like growth factor I receptor antagonists), SRC inhibitors(Tyrosine-protein kinase SRC inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H31N9O |
InChIKeyALKJNCZNEOTEMP-UHFFFAOYSA-N |
CAS Registry898280-07-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lymphoma | Phase 1 | US | 01 Sep 2007 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Phase 1 | US | 01 May 2007 | |
Philadelphia positive acute lymphocytic leukaemia | Phase 1 | US | 01 May 2007 |
Phase 1 | - | caisukuzlm(wrcjdqfvpd) = requiring dose skipping tmqwkwqnzl (nrsfiizros ) View more | Positive | 20 May 2009 |